针对长非编码RNA H19作为肝脏疾病治疗策略
Yulan Shi1, Fenghua Qu1, Shiyun Zeng2
1Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine China Three Gorges University, China; College of Medicine and Health Science, China Three Gorges University Yichang, 443002, China.
Progress in biophysics and molecular biology
|October 2, 2024
概括
像H19一样的长非编码RNA (lncRNAs) 在肝脏疾病中起着关键作用. 了解H19调控提供了关于肝脏病理和潜在的新疗法的见解.
科学领域:
- 分子生物学分子生物学
- 肝病学 肝病学是一种肝病学.
- 遗传学 是一个遗传学.
背景情况:
- 肝脏调节新陈代谢平衡; 慢性肝脏疾病显著损害健康.
- 长非编码RNAs (lncRNAs) 越来越多地被认为在肝脏疾病的发病过程中发挥着关键作用.
- H19是一种内源性非编码RNA,通过表观遗传修饰影响生物过程.
研究的目的:
- 审查肝病进展中H19调节的分子机制.
- 突出H19作为肝脏疾病的潜在治疗点.
- 提供关于肝脏病理的分子基础的见解.
主要方法:
- 关于H19和肝脏疾病研究的文献综述.
- 对涉及H19.9的表观遗传机制的分析.
- 对H19在肝脏病理学中的作用的当前知识的综合.
主要成果:
- H19与各种肝脏疾病的发病有关.
- H19通过表观遗传修饰影响细胞过程.
- H19的失调与疾病的进展有关.
结论:
- H19是肝脏疾病的关键调节剂.
- 向H19可能会提供一种新的治疗策略.
- 对H19机制的进一步研究可以加深对肝脏疾病的理解.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K